共 50 条
- [2] SRD5A1 and SRD5A2 are Associated with Treatment for Benign Prostatic Hyperplasia with the Combination of 5α-Reductase Inhibitors and α-Adrenergic Receptor Antagonists [J]. JOURNAL OF UROLOGY, 2013, 190 (02): : 615 - 619
- [4] 5α-reduction of epitestosterone is catalysed by human SRD5A1 and SRD5A2 and increases androgen receptor transactivation [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2024, 241
- [5] Genetic Analysis of the SRD5A2 Gene in Indian Patients with 5α-Reductase Deficiency [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2009, 22 (03): : 247 - 254
- [8] A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH [J]. PHARMACOGENOMICS JOURNAL, 2004, 4 (04): : 251 - 259
- [9] A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH [J]. The Pharmacogenomics Journal, 2004, 4 : 251 - 259
- [10] Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2017, 14 (11):